view transcript

1980

Bill K. Bowes and associates form Applied Molecular Genetics Inc. in Thousand Oaks, California.

AMGen is a combination of the company's original name, Applied Molecular Genetics.

1989

Amgen received approval for the product Epogen, for the treatment of anemia.

1991

Amgen received FDA approval for Neupogen for the prevention of cancer chemotherapy infections.

1992

Combined sales for EPOGEN® and NEUPOGEN® hits $1 billion.

2002

Amgen acquires Immunex, the developer of ENBREL®.

2012

AMGEN pleaded guilty "of  illegal marketing practices with Aranesp."

2015

Amgen acquires Dezima Pharma for more than $1.55 billion.

California based biotech company, Amgen (AMGN - Get Report) , reported earnings Tuesday, Jan. 29, 2019.

The results were strong for both the fourth quarter and 2018 as a whole, but fell in after-hours trading anyway after issuing what Wall Street saw as a disappointing 2019 outlook. 

Amgen was established in 1980 in Thousand Oaks, California. The company is the brainchild of venture capitalist William K. (Bill) Bowes. Watch the video above to see how a staff of three turned this small idea into one of the world's leading biotechnology companies. The company's mission is posted on YouTube here.

Amgen is a holding in Jim Cramer's Action Alerts PLUSRead the team's take Amgen Beats but Questions About Guidance Push Shares Lower. Not a member? That's o.k. 

Get access to the best stock picks in Jim Cramer's investment portfolio by executing a two-minute drill on our Big Game Special on Action Alerts PLUS, Jim's VIP club for investors. Sign up now through Feb. 4 and receive 58% off of the normal subscription price. Now that's a real touchdown!